BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24136868)

  • 1. Adjusting overall survival for treatment switches: commonly used methods and practical application.
    Watkins C; Huang X; Latimer N; Tang Y; Wright EJ
    Pharm Stat; 2013; 12(6):348-57. PubMed ID: 24136868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.
    Latimer NR; Abrams KR; Siebert U
    BMC Med Res Methodol; 2019 Mar; 19(1):69. PubMed ID: 30935369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?
    Latimer NR; White IR; Abrams KR; Siebert U
    Stat Methods Med Res; 2019 Aug; 28(8):2475-2493. PubMed ID: 29940824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The net benefit for time-to-event outcome in oncology clinical trials with treatment switching.
    Fukuda M; Sakamaki K; Oba K
    Clin Trials; 2023 Dec; 20(6):670-680. PubMed ID: 37455538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjusting for treatment switching in randomised controlled trials - A simulation study and a simplified two-stage method.
    Latimer NR; Abrams KR; Lambert PC; Crowther MJ; Wailoo AJ; Morden JP; Akehurst RL; Campbell MJ
    Stat Methods Med Res; 2017 Apr; 26(2):724-751. PubMed ID: 25416688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved two-stage estimation to adjust for treatment switching in randomised trials: g-estimation to address time-dependent confounding.
    Latimer NR; White IR; Tilling K; Siebert U
    Stat Methods Med Res; 2020 Oct; 29(10):2900-2918. PubMed ID: 32223524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
    Eaton A; Therneau T; Le-Rademacher J
    Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study.
    Latimer NR; Abrams KR; Lambert PC; Morden JP; Crowther MJ
    Stat Methods Med Res; 2018 Mar; 27(3):765-784. PubMed ID: 27114326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Validation Study of the Rank-Preserving Structural Failure Time Model: Confidence Intervals and Unique, Multiple, and Erroneous Solutions.
    Ouwens M; Hauch O; Franzén S
    Med Decis Making; 2018 May; 38(4):509-519. PubMed ID: 29607730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ipcwswitch: An R package for inverse probability of censoring weighting with an application to switches in clinical trials.
    Grafféo N; Latouche A; Le Tourneau C; Chevret S
    Comput Biol Med; 2019 Aug; 111():103339. PubMed ID: 31442762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjustment for treatment changes in epilepsy trials: A comparison of causal methods for time-to-event outcomes.
    Dodd S; Williamson P; White IR
    Stat Methods Med Res; 2019 Mar; 28(3):717-733. PubMed ID: 29117780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjusting survival time estimates to account for treatment switching in randomized controlled trials--an economic evaluation context: methods, limitations, and recommendations.
    Latimer NR; Abrams KR; Lambert PC; Crowther MJ; Wailoo AJ; Morden JP; Akehurst RL; Campbell MJ
    Med Decis Making; 2014 Apr; 34(3):387-402. PubMed ID: 24449433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methods for adjusting for bias due to crossover in oncology trials.
    Ishak KJ; Proskorovsky I; Korytowsky B; Sandin R; Faivre S; Valle J
    Pharmacoeconomics; 2014 Jun; 32(6):533-46. PubMed ID: 24595585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse events in single-arm clinical trials with non-fatal time-to-event efficacy endpoint: from clinical questions to methods for statistical analysis.
    Tassistro E; Bernasconi DP; Valsecchi MG; Antolini L
    BMC Med Res Methodol; 2024 Jan; 24(1):3. PubMed ID: 38172810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing phase II studies in cancer with time-to-event endpoints.
    Owzar K; Jung SH
    Clin Trials; 2008; 5(3):209-21. PubMed ID: 18559409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring event times in early phase clinical trials: some practical issues.
    Thall PF; Wooten LH; Tannir NM
    Clin Trials; 2005; 2(6):467-78. PubMed ID: 16422307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation.
    Jönsson L; Sandin R; Ekman M; Ramsberg J; Charbonneau C; Huang X; Jönsson B; Weinstein MC; Drummond M
    Value Health; 2014 Sep; 17(6):707-13. PubMed ID: 25236994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.